UK researchers present dengue virus transm...Scientists at Imperial College London have created a worldwide atlas of dengue virus transmission with much higher spatial resolution than any previous regional- or global-scale estimates. more ➔
AMR: IMIs Enable project reaches endpoin...The ENABLE project has achieved its initial goals to identify three antibacterial leads, select two antibacterial development candidates and advance one compound into Phase I development. more ➔
MercachemSyncom, Bionetix, and ProQinase i...Bionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing more ➔
iOnctura SA bags €15m in Series A roundMerck KGaAs 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic. more ➔
Agriculture ministers commit to global tra...Ministers from 72 countries came together at the Berlin Agriculture Ministers conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based … more ➔
HepaRegeniX: €11m for liver disease trea...HepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic. more ➔
Nestlé heavily invests in sustainable pac... Swiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives. more ➔
BioNTech acquires Neon at cheapest for $67...mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US. more ➔
New stromal target overcomes cancer resist...British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models. more ➔
Astellas and Adaptimmune team up in CAR-T...Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells. more ➔
